Conatus Pharmaceuticals (Conatus Pharmaceuticals) Cash-to-Debt : 78.82 (As of Mar. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Conatus Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Conatus Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2020 was 78.82.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Conatus Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2020.

The historical rank and industry rank for Conatus Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

CNAT's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.5
* Ranked among companies with meaningful Cash-to-Debt only.

Conatus Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Conatus Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Conatus Pharmaceuticals Cash-to-Debt Chart

Conatus Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Cash-to-Debt

Get a 7-Day Free Trial

36.51

77.02

5.69

No Debt

61.25

Conatus Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Cash-to-Debt	Get a 7-Day Free Trial															53.96	53.74	51.67	61.25	78.82

Competitive Comparison of Conatus Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Conatus Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Conatus Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conatus Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Conatus Pharmaceuticals's Cash-to-Debt falls into.

Conatus Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Conatus Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	20.703	/	(0.338	+	0)
	=	61.25

Conatus Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2020 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	18.049	/	(0.229	+	0)
	=	78.82

Conatus Pharmaceuticals (NAS:CNAT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Conatus Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Conatus Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

16745 West Bernardo Drive, Suite 250, San Diego, CA, USA, 92127

Website

https://www.conatuspharma.com

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.